rTMS real stimulation stage1 for Parkinson's (NCT06002581)
Magnetic stimulation slows Parkinson progression
- Trial ID
- NCT06002581
- Official Title
- Clinical Study on the Efficacy and Safety of rTMS Regulating Slow-wave Sleep to Delay the Progression of Parkinson's Disease
- Goal
- Magnetic stimulation slows Parkinson progression
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Study Type
- INTERVENTIONAL
- Enrollment
- 56 participants
- Conditions
- Parkinson's Disease
- Interventions
- rTMS real stimulation stage1, rTMS shame stimulation stage1, rTMS real stimulation stage 2
Summary For Families
Goal: The trial aims to slow Parkinson's progression by boosting deep slow-wave sleep, which may help the brain clear toxic proteins and support repair and plasticity linked to symptom worsening. Approach: It uses repetitive transcranial magnetic stimulation, noninvasive magnetic pulses to targeted brain regions to increase slow-wave non-REM sleep; rTMS does not change levodopa itself, so participants keep a stable levodopa dose while researchers test whether better slow-wave sleep affects symptoms or disease course. Eligibility: The study is enrolling right-handed Chinese Han adults aged 50 to 80 with clinically probable or definite PD at Hoehn-Yahr stages 1,4, on a stable levodopa regimen, without major cognitive impairment, prior brain surgery or TMS, significant sleep apnea or other listed contraindications.
Locations
- Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying rTMS real stimulation stage1. Goal: The trial aims to slow Parkinson's progression by boosting deep slow-wave sleep, which may help the brain clear toxic proteins and support repair and plasticity linked to symptom worsening. Approach: It uses repetitive transcranial magnetic stimulation, noninvasive magnetic pulses to targeted brain regions to increase slow-wave non-REM sleep; rTMS does not change levodopa itself, so participants keep a stable levodopa dose while researchers test whether better slow-wave sleep affects symptoms or disease course. Eligibility: The study is enrolling right-handed Chinese Han adults aged 50 to 80 with clinically probable or definite PD at Hoehn-Yahr stages 1,4, on a stable levodopa regimen, without major cognitive impairment, prior brain surgery or TMS, significant sleep apnea or other listed contraindications.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 11 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.